



## Pharmacy and Therapeutics Advisory Forum

Hilton Garden Inn  
9850 Park Plaza Ave  
Louisville, KY 40241

August 26, 2019  
8:30 AM – 10:00 AM

### Agenda

- I. Call to Order – WellCare Introductions & Announcements
- II. Old Business – Updates from May 20 , 2019 P&T Meeting
- III. New Business
  - a. Drug Class Reviews

Drug Class
Vaccines
Toxoids
Passive Immunizing Agents
Antineoplastic Agents
Antihistamines
Decongestants
Cough/Cold
Antiasthmatics
Misc. Respiratory
Ophthalmic
Otic
Mouth & Throat
Anorectal



## Pharmacy and Therapeutics Advisory Forum

Dermatological
----------------

### b. Speaker Drug Reviews (\*Requests to present must be submitted prior to meeting)

#### IV. New Drugs to Market

##### a. Drug Reviews

Brand name (generic)	FDA Approval Date	Market/Launch Date
ADHANSIA XR <sup>TM</sup> (methylphenidate extended-release) New Formulation"	2/27/2019	6/18/2019
ANNOVERA <sup>TM</sup> (segesterone/ ethinyl estradiol) New Combination	8/10/2018	7/12/2019
EMGALITY <sup>TM</sup> 100mg/mL (galcanezumab-gnlm) New Formulation	6/4/2019	6/6/2019
Evekeo ODT <sup>TM</sup> (amphetamine) New Formulation	1/30/2019	6/28/2019
Ezallor <sup>TM</sup> (rosuvastatin) New Formulation	12/18/2018	6/24/2019
KANJINTI <sup>TM</sup> (trastuzumab-anns) New Biosimilar	6/13/2019	7/22/2019
KATERZIA <sup>TM</sup> (amlodipine) New Formulation	7/8/2019	7/16/2019
Levothyroxine <sup>®</sup> New Formulation	4/11/2019	5/28/2019
MVASI <sup>TM</sup> (bevacizumab-awwb) New Biosimilar	9/14/2017	7/22/2019



## Pharmacy and Therapeutics Advisory Forum

Brand name (generic)	FDA Approval Date	Market/Launch Date
NUBEQA <sup>®</sup> (darolutamide) New Molecular Entity	7/30/2019	7/31/2019
NUCALA <sup>®</sup> for self-administration (mepolizumab) New Formulation	6/6/2019	6/11/2019
PIQRAY <sup>®</sup> (alpelisib) New Molecular Entity	5/24/2019	5/30/2019
POLIVY <sup>™</sup> (polatuzumab vedotin) New Biologic	6/10/2019	6/11/2019
Ruzurgi <sup>®</sup> (amifampridine) New Formulation	5/6/2019	6/6/2019
(Selenious acid) New Molecular Entity	4/30/2019	7/11/2019
Slynd (drospirenone) New Formulation	5/23/2019	7/2/2019
Sunosi <sup>™</sup> (solriamfetol) New Molecular Entity	3/20/2019	7/2/2019
SYMDEKO <sup>™</sup> 50-70MG (tezacaftor/ ivacaftor and ivacaftor) New Formulation	6/21/2019	6/25/2019
Symjepi <sup>®</sup> (epinephrine 0.15 mg) New Formulation	9/27/2018	7/3/2019
Thiola <sup>®</sup> EC (tiopronin) New Formulation	6/28/2019	7/9/2019
TURALIO <sup>™</sup> (pexidartinib) New Molecular Entity	8/2/2019	8/5/2019
VYLEESI <sup>™</sup> (bremelanotide) New Molecular Entity	6/21/2019	8/5/2019



## Pharmacy and Therapeutics Advisory Forum

Brand name (generic)	FDA Approval Date	Market/Launch Date
Xpovio™ (selinexor) New Molecular Entity	7/3/2019	7/9/2019
Zolgensma® (onasemnogene abeparvovec) New Biologic	5/17/2019	5/29/2019
Zulresso™ (brexanolone) New Molecular Entity	3/19/2019	6/19/2019

### V. Adjournment

#### a. Future Meeting Dates

November 25, 2019

<https://www.wellcare.com/Kentucky/Providers/Medicaid/Pharmacy/Pharmacy-and-Therapeutics-Advisory-Forum>